Type 1 diabetes care is entering a new era — here's what's driving the shift

The treatment of type 1 diabetes is on the cusp of a major transformation. At the Breakthrough T1D Clinical and Research Congress, Dr. Chantal Mathieu of KU Leuven outlined three converging frontiers — smart technology, immunotherapy, and stem cell science — that are reshaping how the disease is managed and, potentially, how it could one day be cured.

On the technology front, AI-powered insulin pumps are rapidly evolving into what experts call an "artificial pancreas" — systems that continuously monitor glucose and automatically adjust insulin delivery based on meals, exercise, and other real-time signals. Meanwhile, the approval of teplizumab (Tzield) to delay type 1 diabetes onset has made early screening more critical than ever, with Italy already mandating childhood screening by law. And in stem cell research, pluripotent stem cell technology now enables large-scale production of beta cells, raising hopes for a functional cure.

Key Takeaways:

• AI-driven closed-loop insulin systems are expected to become standard of care in the near term
• Teplizumab's approval has opened the door to treating people who test positive for T1D autoantibodies — before full disease onset
• Combining beta cell transplantation with immunotherapy could potentially halt autoimmune destruction and offer a cure

Why it matters: These advances signal a shift from managing type 1 diabetes to potentially preventing and curing it — a milestone that could dramatically improve quality of life for millions worldwide.